Literature DB >> 3136790

Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.

F Pisani1, A Fazio, G Oteri, E Spina, E Perucca, L Bertilsson.   

Abstract

The single oral dose pharmacokinetics of carbamazepine-10, 11-epoxide (CBZ-E) were investigated in six normal volunteers during a control session and during concurrent treatment with valpromide (VPM) (300 mg twice daily for 8 days). VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01). These results suggest that the elevation of plasma CBZ-E levels in patients receiving carbamazepine and VPM in combination is due to inhibition of epoxide hydrolase in the liver.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3136790      PMCID： PMC1386437          DOI： 10.1111/j.1365-2125.1988.tb03354.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  Rapid quantitation of N-dipropylacetamide in human plasma by gas-liquid chromatography.

Authors:  F Pisani; R Di Perri; G Nistico
Journal:  J Chromatogr       Date:  1979-06-01

2.  Valpromide inhibits human epoxide hydrolase.

Authors:  G M Pacifici; M Franchi; C Bencini; A Rane
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

3.  Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients.

Authors:  F Pisani; A Fazio; G Oteri; C Ruello; C Gitto; F Russo; E Perucca
Journal:  Epilepsia       Date:  1986 Sep-Oct       Impact factor: 5.864

4.  Possible hazard of valpromide-carbamazepine combination therapy in epilepsy.

Authors:  J W Meijer; C D Binnie; R M Debets; J A van Parys; N K de Beer-Pawlikowski
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

5.  A study on the metabolism of dipropylacetamide to dipropylacetic acid in rats.

Authors:  F Pisani; A Fazio; G Oteri; R Di Perri
Journal:  J Pharm Pharmacol       Date:  1982-01       Impact factor: 3.765

6.  Valpromide/carbamazepine and risk of teratogenicity.

Authors:  G M Pacifici; T Tomson; L Bertilsson; A Rane
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide.

Authors:  T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

9.  Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.

Authors:  M Bialer; A Rubinstein; I Raz; O Abramsky
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
  9 in total
  8 in total

Review 1.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

2.  Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine.

Authors:  D K Robbins; P J Wedlund; R Kuhn; R J Baumann; R H Levy; S L Chang
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 3.  Clinical pharmacology of valpromide.

Authors:  M Bialer
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

4.  Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients.

Authors:  Yukiko Nakajima; Yoshiro Saito; Kisho Shiseki; Hiromi Fukushima-Uesaka; Ryuichi Hasegawa; Shogo Ozawa; Kenji Sugai; Masaaki Katoh; Osamu Saitoh; Teiichi Ohnuma; Mitsuru Kawai; Taisuke Ohtsuki; Chieko Suzuki; Narihiro Minami; Hideo Kimura; Yu-ichi Goto; Naoyuki Kamatani; Nahoko Kaniwa; Jun-ichi Sawada
Journal:  Eur J Clin Pharmacol       Date:  2005-02-04       Impact factor: 2.953

5.  Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.

Authors:  A Haj-Yehia; M Bialer
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

6.  Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects.

Authors:  F Pisani; A Fazio; C Artesi; G Oteri; E Spina; T Tomson; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

7.  The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites.

Authors:  J J Muñoz; R E De Salamanca; C Diaz-Obregón; F L Timoneda
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 8.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.